Argenx SE Stock Swings Amid FDA Scrutiny of Vyvgart Hytrulo
Argenx SE’s stock price has fluctuated amid regulatory scrutiny over its Vyvgart Hytrulo treatment, but analyst ratings have helped stabilize the stock.
2 minutes to read
Arngenx SE Stock Falls as FDA Reviews Safety of Vyvgart Hytrulo Treatment
Argenx SE’s stock price has declined due to the FDA’s evaluation of safety concerns surrounding its Vyvgart Hytrulo treatment.
One minute to read
Argenx SE’s Vyvgart Approval: Breakthrough or Bubble?
Argenx SE’s approval of its subcutaneous treatment Vyvgart for CIDP has sparked debate over whether it’s a genuine breakthrough or market manipulation.
2 minutes to read
Argenx SE Secures EU Approval for VYVGART, Expanding CIDP Treatment Options
Argenx SE has secured European Commission approval for its VYVGART subcutaneous injection, a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), expanding its market reach to 27 EU countries.
2 minutes to read
Argenx SE Secures EU Approval for VYVGART: Will Investors Finally Take Notice?
Argenx SE has secured European Commission approval for its VYVGART treatment, a major milestone that could lead to significant growth, but investors have yet to take notice.
2 minutes to read
Argenx Unveils Promising Efgartigimod Data for Myositis and Sjogren’s at EULAR 2025
Argenx presents positive phase 2 proof-of-concept results for its efgartigimod asset in treating myositis and Sjogren’s disease at the EULAR 2025 conference.
One minute to read
Argenx SE Advances in Autoimmune and Cancer Therapies with Promising efgartigimod Results
Argenx SE has made significant strides in autoimmune disease and cancer therapies, with positive Phase 2 results for its efgartigimod treatment and FDA Fast Track designation for Sjogren’s disease treatment.
One minute to read
Argenx SE Reports Promising Trial Results for Efgartigimod, Boosting Stock Amid FDA Fast Track Designation
Argenx SE presents positive trial data for its treatment efgartigimod, showing significant improvement in patients with myositis and Sjogren’s disease.
One minute to read
Argenx SE Reports Promising Trial Results for Efgartigimod, Boosting Stock Amid FDA Fast Track Designation
Argenx SE presents positive trial data for its treatment efgartigimod, showing significant improvement in patients with myositis and Sjogren’s disease.
One minute to read
Argenx Sustains Market Leadership with Strong RS Rating and Resilient Stock Performance
Argenx has maintained its market leadership position, with a strong stock price and technical indicators suggesting continued momentum.
One minute to read